Home ETF List About

ETF Holdings Breakdown of REGN

Stock NameRegeneron Pharmaceuticals Inc
TickerREGN(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS75886F1075
LEI549300RCBFWIRX3HYQ56

REGN institutional holdings

The following institutional investment holdings of REGN have been identified

Date ETF ISIN/Name Num Shares Book value
2025-09-26 IE00B5BMR087 (iShares Core S&P 500 UCITS ETF USD (Acc)) 240,748USD 135,757,797
2025-09-26 IE00BD8KRH84 (iShares Core S&P 500 UCITS ETF GBP Hedged (Dist)) 240,748USD 135,757,797
2025-09-26 IE00BL3J3G74 (iShares Core S&P 500 UCITS ETF MXN Hedged (Acc)) 240,748USD 135,757,797
2025-09-26 IE00B4L5Y983 (iShares Core MSCI World UCITS ETF USD (Acc)) 160,106USD 90,283,773
2025-09-26 IE00BD45YS76 (iShares Core MSCI World UCITS ETF GBP Hedged (Dist)) 160,106USD 90,283,773
2025-09-26 IE00BKBF6H24 (iShares Core MSCI World UCITS ETF) 160,106 -0.6%USD 90,283,773 0.9%
2025-09-26 IE000OHHIBC6 (iShares Core MSCI World UCITS ETF USD (Dist)) 160,106USD 90,283,773
2025-09-26 IE00BHZPJ890 (iShares MSCI USA ESG Enhanced UCITS ETF USD (Dist)) 11,741USD 6,620,750
2025-09-26 IE0031442068 (iShares Core S&P 500 UCITS ETF USD (Dist)) 36,102USD 20,357,918
2025-09-26 IE00B6R52259 (iShares MSCI ACWI UCITS ETF) 28,016USD 15,798,222
2025-09-26 IE00019GPKX6 (iShares MSCI ACWI UCITS ETF SGD Hedged (Acc)) 28,016USD 15,798,222
2025-09-26 IE00B53SZB19 (iShares NASDAQ 100 UCITS ETF USD (Acc)) 129,603USD 73,083,132
2025-09-26 IE00BYVQ9F29 (iShares NASDAQ 100 UCITS ETF) 129,603USD 73,083,132
2025-09-26 IE00BFNM3G45 (iShares MSCI USA ESG Screened UCITS ETF USD (Acc)) 32,004USD 18,047,056
2025-09-26 IE00BFNM3H51 (iShares MSCI USA ESG Screened UCITS ETF USD (Dist)) 32,004USD 18,047,056
2025-09-26 IE000G2LIHG9 (iShares MSCI USA ESG Screened UCITS ETF EUR Hedged (Acc)) 32,004USD 18,047,056
2025-09-26 IE00BMTX1Y45 (iShares S&P 500 Swap UCITS ETF USD (Acc)) 14,199 200.0%USD 8,006,816 198.5%
2025-09-26 IE000D3BWBR2 (iShares S&P 500 Swap UCITS ETF USD (Dist)) 14,199USD 8,006,816
2025-09-26 IE00B0M62Q58 (iShares MSCI World UCITS ETF USD (Dist)) 11,408USD 6,432,971
2025-09-26 IE00B3ZW0K18 (iShares S&P 500 EUR Hedged UCITS ETF (Acc)) 16,345USD 7,883,121
2025-09-26 IE00BHZPJ569 (iShares MSCI World ESG Enhanced UCITS ETF USD Acc GBP) 2,341USD 1,320,090
2025-09-26 IE00BG11HV38 (iShares MSCI World ESG Enhanced UCITS ETF USD Inc GBP) 2,341USD 1,320,090
2025-09-26 IE00BFNM3K80 (iShares MSCI World ESG Screened UCITS ETF USD (Dist)) 8,063USD 4,546,726
2025-09-26 IE00BFNM3J75 (iShares MSCI World ESG Screened UCITS ETF) 8,063USD 4,546,726
2025-09-26 IE0003WV2ME7 (iShares S&P 500 Equal Weight UCITS ETF GBP Hedged (Acc)) 16,858USD 9,506,226
2025-09-26 IE000MLMNYS0 (iShares S&P 500 Equal Weight UCITS ETF USD (Acc)) 16,858USD 9,506,226
2025-09-26 IE00B8FHGS14 (iShares Edge MSCI World Minimum Volatility UCITS ETF USD (Acc)) 13,836USD 7,802,120 1.5%
2025-09-26 IE00BGPP8L80 (iShares Edge MSCI World Minimum Volatility UCITS ETF GBP Hedged (Acc)) 13,836USD 7,802,120
2025-09-26 IE00B441G979 (iShares MSCI World EUR Hedged UCITS ETF (Acc)) 7,178USD 3,461,918
2025-09-26 IE00B43HR379 (iShares S&P 500 Health Care Sector UCITS ETF USD (Acc)) 48,267USD 27,217,761
2025-09-26 IE00BMBKBZ46 (iShares S&P 500 Health Care Sector UCITS ETF) 48,267USD 27,217,761
2025-09-26 IE00B52SFT06 (iShares MSCI USA UCITS ETF USD (Acc)) 4,480USD 2,526,272
2025-09-26 IE00B6SPMN59 (iShares Edge S&P 500 Minimum Volatility UCITS ETF USD (Acc)) 7,650USD 4,313,835
2025-09-26 IE00BD93YH54 (iShares Edge S&P 500 Minimum Volatility UCITS ETF USD (Dist)) 7,650USD 4,313,835
2025-09-26 IE00B57X3V84 (iShares Dow Jones Global Sustainability Screened UCITS ETF USD (Acc)) 8,714USD 4,913,825
2025-09-26 IE00B14X4M10 (iShares MSCI North America UCITS ETF USD (Dist) USD) 2,311USD 1,303,173
2025-09-26 IE00BKVL7778 (iShares Edge MSCI World Minimum Volatility ESG UCITS ETF USD (Acc)) 8,782USD 4,952,170
2025-09-26 IE00BJ5JNZ06 (iShares MSCI World Health Care Sector ESG UCITS ETF) 2,748 4.0%USD 1,549,597 5.5%
2025-09-26 IE0009QS7W62 (iShares MSCI World Health Care Sector ESG UCITS ETF USD (Acc)) 2,748USD 1,549,597
2025-09-26 IE00BMXC7V63 (iShares S&P 500 Paris-Aligned Climate UCITS ETF USD (Acc)) 3,272USD 1,845,081
2025-09-26 IE000G4PH2B1 (iShares S&P 500 Paris-Aligned Climate UCITS ETF USD Dist) 3,272USD 1,845,081
2025-09-26 IE00B3Y8X563 (iShares S&P 500 GBP Hedged UCITS ETF (Acc)) 2,440USD 1,026,688 1.1%
2025-09-26 IE00B27YCN58 (iShares MSCI World Islamic UCITS ETF USD (Dist) USD) 4,405USD 2,483,980
2025-09-26 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 58,584USD 33,035,518
2025-09-26 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 58,584USD 33,035,518
2025-09-26 IE000R9FA4A0 (iShares S&P 500 ESG UCITS ETF USD (Acc)) 1,973USD 1,112,575
2025-09-26 IE00BN92ZL31 (iShares MSCI World Paris-Aligned Climate UCITS ETF USD (Dist)) 673USD 379,505
2025-09-26 IE00BMXC7W70 (iShares MSCI World Paris-Aligned Climate UCITS ETF USD (Acc)) 673USD 379,505
2025-09-26 IE00BKVL7331 (iShares Edge MSCI USA Minimum Volatility ESG UCITS ETF USD (Acc)) 1,602USD 903,368
2025-09-26 IE00B42YS929 (iShares MSCI World GBP Hedged UCITS ETF (Acc)) 661USD 278,131
2025-09-26 IE00B296QM64 (iShares MSCI USA Islamic UCITS) 2,354USD 1,327,421 1.5%
2025-09-26 IE0002EKOXU6 (iShares Russell 1000 Value UCITS ETF) 731USD 412,211
Total =2,248,127 USD 1,265,355,401
Book value of shares is calculated on the adjusted close price of each day (row).

News associated with REGN

Regeneron And Sanofi : CHMP Recommends EU Approval Of Dupixent For Chronic Spontaneous Urticaria
(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion recommending the approval of Dupixent (dupilumab) in the European Union for treating c - 2025-09-22 02:12:20
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of “Moderate Buy” by Brokerages
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) have been given an average recommendation of “Moderate Buy” by the twenty-six analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have assigned a buy rating and three […] - 2025-08-26 02:16:48
LABU, INCY, UTHR, REGN: ETF Outflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Direxion Daily S&P Biotech Bull 3x Shares (Symbol: LABU) where we have detected an approximate $67.3 million dollar outflow -- that's a 9.4% dec - 2025-08-20 12:04:03
Regeneron Pharmaceuticals (NASDAQ:REGN) versus Cadrenal Therapeutics (NASDAQ:CVKD) Head-To-Head Analysis
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) and Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings. Volatility and Risk Regeneron Pharmaceuticals has a beta […] - 2025-08-20 02:22:48
Truist Financial Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $812.00
Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price target reduced by Truist Financial from $940.00 to $812.00 in a research note published on Monday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. REGN has been the topic of several other reports. The Goldman Sachs Group dropped their price target on […] - 2025-08-14 03:00:52
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Raised by Blair William & Co. IL
Blair William & Co. IL lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.2% in the 1st quarter, Holdings Channel reports. The fund owned 1,282 shares of the biopharmaceutical company’s stock after buying an additional 27 shares during the period. Blair William & Co. IL’s holdings in Regeneron Pharmaceuticals were worth […] - 2025-08-11 06:26:50
Harbour Investments Inc. Sells 32 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Harbour Investments Inc. reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 7.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 403 shares of the biopharmaceutical company’s stock after selling 32 shares during the quarter. Harbour Investments Inc.’s holdings in […] - 2025-08-07 09:40:47
409 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Purchased by Arkadios Wealth Advisors
Arkadios Wealth Advisors purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 409 shares of the biopharmaceutical company’s stock, valued at approximately $259,000. Several other institutional investors and hedge funds also […] - 2025-08-07 05:38:53
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, BMO Capital Markets Analyst Says
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price target upped by stock analysts at BMO Capital Markets from $600.00 to $640.00 in a research report issued on Monday,Benzinga reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price target indicates a potential upside of 12.30% from […] - 2025-08-06 03:12:48
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $828.86 Consensus Target Price from Brokerages
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has been given a consensus rating of “Moderate Buy” by the twenty-four ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, fifteen have assigned a buy recommendation and two […] - 2025-08-04 02:59:01
Nasdaq 100 Movers: MRVL, REGN
In early trading on Friday, shares of Regeneron Pharmaceuticals, topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.6%. Year to date, Regeneron Pharmaceuticals, has lost about 20.7% of its value. And the worst performing Nasdaq 100 co - 2025-08-01 11:30:09
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Choreo LLC
Choreo LLC boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 0.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,746 shares of the biopharmaceutical company’s stock after acquiring an additional 32 shares during the period. Choreo LLC’s holdings in Regeneron Pharmaceuticals […] - 2025-07-24 07:22:56
Crestwood Advisors Group LLC Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Crestwood Advisors Group LLC increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 467 shares of the biopharmaceutical company’s stock after purchasing an additional 25 shares during the quarter. Crestwood Advisors Group […] - 2025-07-24 05:47:12
Kestra Private Wealth Services LLC Has $1.31 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Kestra Private Wealth Services LLC grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 6.9% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,058 shares of the biopharmaceutical company’s stock after buying an additional 132 shares during the quarter. […] - 2025-07-23 07:50:58
Larson Financial Group LLC Has $34,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Larson Financial Group LLC lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 34.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 53 shares of the biopharmaceutical company’s stock after selling 28 shares during the quarter. Larson […] - 2025-07-23 06:30:53
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Alps Advisors Inc.
Alps Advisors Inc. raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 71.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 530 shares of the biopharmaceutical company’s stock after purchasing an additional 220 shares during the quarter. Alps Advisors Inc.’s […] - 2025-07-17 05:50:54
Stratos Wealth Partners LTD. Sells 115 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Stratos Wealth Partners LTD. trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 18.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 506 shares of the biopharmaceutical company’s stock after selling 115 shares during the period. Stratos Wealth Partners […] - 2025-07-16 04:58:54
Allworth Financial LP Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Allworth Financial LP trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 14.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 821 shares of the biopharmaceutical company’s stock after selling 137 shares during the period. Allworth Financial […] - 2025-07-15 08:20:00
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $584.00
Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price target increased by UBS Group from $560.00 to $584.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock. Several other research analysts also recently commented on REGN. BMO Capital Markets reduced their price objective on Regeneron […] - 2025-07-14 03:30:48
Brown Advisory Inc. Reduces Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Brown Advisory Inc. lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,269 shares of the biopharmaceutical company’s stock after selling 247 shares during the quarter. Brown Advisory Inc.’s […] - 2025-07-13 05:54:54
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Cut by D.A. Davidson & CO.
D.A. Davidson & CO. reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.8% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 732 shares of the biopharmaceutical company’s stock after selling 21 shares during the quarter. D.A. […] - 2025-07-11 05:32:52
Brokerages Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) PT at $813.57
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has received an average recommendation of “Moderate Buy” from the twenty-five ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating, fifteen have assigned a buy rating and three have issued […] - 2025-07-10 03:07:00
DAVENPORT & Co LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
DAVENPORT & Co LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 427 shares of the biopharmaceutical company’s stock, valued at approximately $271,000. A number of other institutional […] - 2025-07-09 05:11:22
Bessemer Group Inc. Sells 3,860 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Bessemer Group Inc. decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 76.0% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,218 shares of the biopharmaceutical company’s stock after selling 3,860 shares during the period. Bessemer Group […] - 2025-07-01 05:46:52
Golden State Wealth Management LLC Has $60,000 Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Golden State Wealth Management LLC increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 265.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 95 shares of the biopharmaceutical company’s stock after purchasing an additional […] - 2025-07-01 05:46:50
Spire Wealth Management Has $114,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Spire Wealth Management raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 13.9% during the 1st quarter, Holdings Channel reports. The institutional investor owned 180 shares of the biopharmaceutical company’s stock after purchasing an additional 22 shares during the quarter. Spire Wealth Management’s holdings in Regeneron Pharmaceuticals were worth $114,000 as of […] - 2025-07-01 05:46:49
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Blue Trust Inc.
Blue Trust Inc. raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 18.2% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 331 shares of the biopharmaceutical company’s stock after acquiring an additional 51 shares during the period. Blue Trust Inc.’s holdings in Regeneron Pharmaceuticals […] - 2025-06-24 05:02:59
Regeneron, Sanofi: FDA Approves Dupixent To Treat Adult Patients With Bullous Pemphigoid
(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and French drug major Sanofi S.A. (SNYNF,SNY) announced Friday that the U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid or BP. - 2025-06-20 02:41:27
Cyndeo Wealth Partners LLC Decreases Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Cyndeo Wealth Partners LLC lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 9.5% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 677 shares of the biopharmaceutical company’s stock after selling 71 shares during the period. Cyndeo Wealth Partners LLC’s holdings […] - 2025-06-18 05:50:55
Exchange Traded Concepts LLC Lowers Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Exchange Traded Concepts LLC decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 45.6% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,352 shares of the biopharmaceutical company’s stock after selling 2,807 shares during the quarter. Exchange Traded […] - 2025-06-18 05:13:06

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.